Medicaid spending on Ozempic, other GLP-1 drugs, topped $1B in 2022

Medicaid spent $1.1 billion on Ozempic and other GLP-1 drugs that can be used for weight loss in 2022, a KFF analysis published Sept. 8 found. 

Ozempic accounts for the majority of this spending, with Medicaid paying $912.3 million for the drug for 978,400 Medicaid recipients. The drug, manufactured by Novo Nordisk, is used to treat Type 2 diabetes but has been prescribed off-label for weight loss. 

Spending on GLP-1 drugs in Medicaid nearly doubled between 2021 and 2022, rising from $547 million in 2021.  

According to KFF's analysis, it is difficult to determine how much of the spending on GLP-1 drugs is tied to weight loss or diabetes treatment. Medicaid programs in 10 states provide broad coverage of weight-loss medications, according to Bloomberg. 

Read the full analysis here. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Top 40 articles from the past 6 months